Atovaquone-Proguanil (Malarone) Dosing and Contraindications
For malaria prophylaxis, atovaquone-proguanil should be dosed as one adult tablet (250mg atovaquone/100mg proguanil) daily starting 1-2 days before travel, continued throughout exposure, and for 7 days after leaving the malaria-endemic area; for treatment of uncomplicated malaria, the dose is 4 adult tablets once daily for 3 consecutive days. 1, 2, 3
Prophylaxis Dosing
Adults and Children >40 kg
- Standard dose: 1 adult tablet (250mg/100mg) once daily
- Timing: Start 1-2 days before entering endemic area
- Duration: Continue daily throughout stay and for 7 days after departure 2, 4
Pediatric Weight-Based Dosing (Prophylaxis)
- 11-20 kg: ¼ adult dose daily
- >20-30 kg: ½ adult dose daily
- >30-40 kg: ¾ adult dose daily
- >40 kg: Full adult dose daily 5
Important Prophylaxis Considerations
- Take with food or milk to enhance absorption (fat increases bioavailability 2-3 fold) 5
- The causal prophylactic activity against hepatic stages is what allows the shortened 7-day post-travel regimen compared to other antimalarials 2, 4
- Efficacy for P. falciparum prophylaxis approaches 98-100% in clinical trials 2, 4
Treatment Dosing for Uncomplicated Malaria
Adults and Children >40 kg
Pediatric Weight-Based Dosing (Treatment)
- 11-20 kg: 1 adult tablet daily × 3 days
- >20-30 kg: 2 adult tablets daily × 3 days
- >30-40 kg: 3 adult tablets daily × 3 days
- >40 kg: 4 adult tablets daily × 3 days 3, 5
Treatment Efficacy
- Cure rate >98% for uncomplicated P. falciparum malaria 3, 6
- Second-line option for patients with contraindications to artemisinin-based combination therapies (ACTs) or those from Southeast Asia with high ACT resistance 1
- For P. vivax/P. ovale: Add primaquine or tafenoquine after atovaquone-proguanil to prevent relapse from hepatic hypnozoites 1
Contraindications and Precautions
Absolute Contraindications
- Severe renal impairment (creatinine clearance <30 mL/min) - atovaquone is predominantly eliminated unchanged and accumulates
- Hypersensitivity to atovaquone or proguanil
- Children <11 kg body weight (safety and efficacy not established) 2, 5
Relative Contraindications and Cautions
- Pregnancy: Limited data available; use only if benefit outweighs risk (not first-line)
- Lactation: Both drugs are excreted in breast milk; use caution
- Severe hepatic impairment: Use with caution as proguanil is hepatically metabolized 5
Drug Interactions
- Rifampin/rifabutin: Significantly reduces atovaquone levels (40-50% decrease); avoid concurrent use
- Metoclopramide: May reduce atovaquone bioavailability
- Tetracycline: May reduce atovaquone plasma concentrations by 40%
- Antiretroviral protease inhibitors: May decrease atovaquone levels
- Proguanil metabolism involves CYP3A4 and CYP2C19, but clinically significant interactions are uncommon 5
Common Pitfalls and Clinical Pearls
Adherence Issues
- The 7-day post-travel continuation is critical - most prophylaxis failures occur when patients stop early 2
- Emerging evidence suggests abbreviated post-travel regimens (stopping 1 day after departure) may be effective, but this is not yet recommended in guidelines due to insufficient evidence and concerns about atovaquone resistance with monotherapy 7, 8, 9
Administration Tips
- Must be taken with food or fatty meal - this is non-negotiable for adequate absorption 5
- If vomiting occurs within 1 hour of dosing, repeat the dose 3
- Treatment-limiting adverse events (primarily vomiting) occur in <1% of patients 6
Adverse Effects
- Most common: abdominal pain, nausea, headache, diarrhea (similar frequency to placebo) 2, 3
- Significantly fewer neuropsychiatric effects than mefloquine 2
- Significantly fewer GI effects than chloroquine plus proguanil 2
- Discontinuation rates due to adverse events are lower than comparator antimalarials 2